Does the increasing placebo response impact outcomes of adult and pediatric ADHD clinical trials? Data from the US Food and Drug Administration 2000

Does the increasing placebo response impact outcomes of adult and pediatric ADHD clinical trials? Data from the US Food and Drug Administration 2000–2009

Published:2017-11 Issue: Volume:94 Page:202-207
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Khan Arif^ORCID,Fahl Mar Kaysee,Brown Walter A.

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference11 articles.

1. Advances in understanding and treating ADHD;Antshel;BMC Med.,2011

2. Using meta-analysis to compare the efficacy of medications for Attention-Deficit/Hyperactivity Disorder in youths;Faraone;P&T,2009

3. Comparing the efficacy of medications for ADHD using meta-analysis;Faraone;MedGenMed,2006

4. A comparison of the efficacy of medications for adult Attention-Deficit/Hyperactivity Disorder using meta-analysis of effect sizes;Faraone;J Clin Psychiatry,2010

5. FDA ACCESS DATA [database Online];Food and Drug Administration,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting;Translational Psychiatry;2023-12-14

2. Interpreting clinical trial outcomes marred by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting;2023-10-04

3. A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence;Psychiatry Research;2023-09

4. Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo;Translational Psychiatry;2023-04-29

5. Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo;2023-02-08